N1-(5-methyl-4-(7-(pyrimidin-5-ylamino)imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane-1,4-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: N1-(5-methyl-4-(7-(pyrimidin-5-ylamino)imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane-1,4-diamine
• 英文别名: 4-N-[5-methyl-4-[7-(pyrimidin-5-ylamino)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]cyclohexane-1,4-diamine
• 化学式: C₂₂H₂₅N₉
• 分子量: 415.501
• InChiKey: MGIDIMZOFJGXKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N1-(5-methyl-4-(7-(pyrimidin-5-ylamino)imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl)cyclohexane-1,4-diamine 、 1-溴-2-氯乙烷 在 potassium phosphate 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以12%的产率得到3-(2-(((1r,4r)-4-(aziridin-1-yl)cyclohexyl)amino)-5-methylpyrimidin-4-yl)-N-(pyrimidin-5-yl)imidazo[1,2-a]pyridin-7-amine
  参考文献：
  名称：

  [EN] DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
  [FR] DÉRIVÉS DE N-CYCLOALKYL/HÉTÉROCYCLOALKYLE-4-(IMIDAZO[1,2-A]PYRIDINE)PYRIMIDIN-2-AMINE EN TANT QU'AGENTS THÉRAPEUTIQUES

  摘要：

  公开号：

  WO2018141002A3

文献信息

• Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
  申请人：Aucentra Therapeutics Pty Ltd

  公开号：US11111245B2

  公开（公告）日：2021-09-07

  A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).

  一类新型蛋白激酶抑制剂，可用于治疗细胞增殖性疾病和病症，特别是以一种或多种 CDK 酶过度表达和/或一种或多种 CDK 活性异常为特征的疾病和病症，包括某些肺癌、乳腺癌、脑癌、卵巢癌、前列腺癌、结直肠癌和白血病。这些抑制剂具有一般结构 (I)。
• DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
  申请人：Aucentra Therapeutics Pty Ltd

  公开号：US20200231586A1

  公开（公告）日：2020-07-23

  A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of one or more CDK enzyme and/or by one or more aberrant CDK activity, including certain cancers of lung, breast, brain, ovary, prostate, colorectal cancer and leukaemias. The inhibitors have the general structure (I).
• [EN] DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS<br/>[FR] DÉRIVÉS DE N-CYCLOALKYL/HÉTÉROCYCLOALKYLE-4-(IMIDAZO[1,2-A]PYRIDINE)PYRIMIDIN-2-AMINE EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：UNIV SOUTH AUSTRALIA

  公开号：WO2018141002A3

  公开（公告）日：2018-11-22